Orphan nuclear receptor PNR/NR2E3 stimulates p53 functions by enhancing p53 acetylation

Molecular and Cellular Biology

Volumn 32, Issue 1, 2012, Pages 26-35

  Wen, Zhi ^a,b   Pyeon, Dohun ^a,b,c   Wang, Yidan ^a   Lambert, Paul ^a   Xu, Wei ^a   Ahlquist, Paul ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN NUCLEAR RECEPTOR; PHOTORECEPTOR SPECIFIC NUCLEAR RECEPTOR; PROTEIN P300; PROTEIN P53; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENETIC SCREENING; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; TRANSCRIPTION INITIATION;

ACETYLATION; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DACTINOMYCIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NEOPLASMS; ORPHAN NUCLEAR RECEPTORS; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863047242     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05513-11     Document Type: Article

References (54)

1. Abrahams A, Parker MI, Prince S. 2010. The T-box transcription factor Tbx2: its role in development and possible implication in cancer. IUBMB Life 62:92-102.
2. Banin S, et al. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
3. Brooks CL, Gu W. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164-171.
4. 2 arrest after DNA damage. Science 282:1497-1501.
5. Choi MY, et al. 2006. A dynamic expression survey identifies transcription factors relevant in mouse digestive tract development. Development 133:4119-4129.
6. Clontech I. 2008. Protocol PT3348-5, version PR842524. http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=17908.
7. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
8. Fojo T. 2002. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Updat. 5:209-216.
9. Gillison ML, Lowy DR. 2004. A causal role for human papillomavirus in head and neck cancer. Lancet 363:1488-1489.
10. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
11. Haider NB, et al. 2000. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat. Genet. 24:127-131.
12. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
13. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
14. Huang Q, et al. 2004. Identification of p53 regulators by genome-wide functional analysis. Proc. Natl. Acad. Sci. U. S. A. 101:3456-3461.
15. Jiang M, Milner J. 2002. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21:6041-6048.
16. Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z. 2007. Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content histograms. Cytometry A 71:125-131.
17. Koopman G, et al. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415-1420.
18. Kruse JP, Gu W. 2009. Modes of p53 regulation. Cell 137:609-622.
19. Lee YF, Lee HJ, Chang C. 2002. Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J. Steroid Biochem. Mol. Biol. 81:291-308.
20. Li M, et al. 2003. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302:1972-1975.
21. Li M, et al. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416:648-653.
22. Li M, Luo J, Brooks CL, Gu W. 2002. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:50607-50611.
23. Liu W, et al. 2006. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem. 281:9837-9840.
24. Luo J, et al. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:2259-2264.
25. Luo J, et al. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
26. Maeda Y, et al. 2006. Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene. Biochem. J. 400:303-313.
27. McInerney EM, et al. 1998. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 12:3357-3368.
28. Mu X, Liu Y, Collins LL, Kim E, Chang C. 2000. The p53/retinoblastoma-mediated repression of testicular orphan receptor-2 in the rhesus monkey with cryptorchidism. J. Biol. Chem. 275:23877-23883.
29. 2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Biochem. Biophys. Res. Commun. 270:1144-1153.
30. Nishimura M, Naito S, Yokoi T. 2004. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. 19:135-149.
31. Peng GH, Ahmad O, Ahmad F, Liu J, Chen S. 2005. The photoreceptorspecific nuclear receptor Nr2e3 interacts with Crx and exerts opposing effects on the transcription of rod versus cone genes. Hum. Mol. Genet. 14:747-764.
32. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5:e1000318.
33. Qi JS, Yuan Y, Desai-Yajnik V, Samuels HH. 1999. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol. Cell. Biol. 19:864-872.
34. Qin J, Chen X, Yu-Lee LY, Tsai MJ, Tsai SY. 2010. Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res. 70:8812-8821.
35. Raman V, et al. 2000. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405:974-978.
36. Reisman D, Loging WT. 1998. Transcriptional regulation of the p53 tumor suppressor gene. Semin. Cancer Biol. 8:317-324.
37. Sayeed A, et al. 2007. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 67:7746-7755.
38. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
39. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
40. Swaroop A, Kim D, Forrest D. 2010. Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina. Nat. Rev. Neurosci. 11:563-576.
41. Sykes SM, et al. 2006. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24:841-851.
42. Takezawa S, et al. 2007. A cell cycle-dependent co-repressor mediates photoreceptor cell-specific nuclear receptor function. EMBO J. 26:764-774.
43. Tanaka T, De Luca LM. 2009. Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res. 69:4945-4947.
44. Tang Y, Luo J, Zhang W, Gu W. 2006. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24:827-839.
45. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. 2008. Acetylation is indispensable for p53 activation. Cell 133:612-626.
46. Thomas MC, Chiang CM. 2005. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 17:251-264.
47. Vassilev LT, et al. 2004. In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 303:844-848.
48. Vaziri H, et al. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
49. Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC. 2003. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J. Biol. Chem. 278:25568-25576.
50. Wei Q. 2005. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells. J. Biol. Chem. 280:37790-37797.
51. Wolkenberg SE, et al. 2006. Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand. Bioorg. Med. Chem. Lett. 16:5001-5004.
52. Yamaguchi H, et al. 2009. p53 acetylation is crucial for its transcriptionindependent proapoptotic functions. J. Biol. Chem. 284:11171-11183.
53. Yu X, Mertz JE. 2003. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J. Virol. 77:2489-2499.
54. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.